肺癌脑转移患者生存预测:基于分子标志物的肺癌分级预后评估更新(Lung-molGPA)
该多机构回顾性数据库分析纳入2006至2014年诊断的2186例非小细胞肺癌(NSCLC)新发脑转移患者,其中腺癌1521例、非腺癌665例,采用多因素Cox回归按风险比加权筛选预后因素,更新为Lung-molGPA。预后因素包括原DS-GPA的4项因素及腺癌患者的EGFR和ALK改变;全队列中位生存12个月,腺癌且Lung-molGPA评分3.5至4.0者中位生存接近4年。作者认为该工具便于临床决策和未来临床试验分层。
要点
- Lung-molGPA在年龄、KPS、颅外转移、脑转移数目基础上纳入腺癌EGFR和ALK改变。
- 全队列中位生存12个月,腺癌评分3.5至4.0者中位生存接近4年。
- 原文为多机构回顾性数据库分析,非腺癌患者未常规检测突变状态。
核心结论
- 近年来NSCLC脑转移患者生存及医生预测生存的能力显著改善。
- 纳入基因改变数据的Lung-molGPA是便于使用的工具,可能有助于临床决策和未来临床试验的适当分层。
研究设计与样本
- 多机构回顾性数据库分析,纳入2006至2014年诊断的2186例NSCLC新发脑转移患者(腺癌1521例,非腺癌665例)。
- 多因素分析于2015年12月至2016年5月进行,预后因素按风险比加权,显著因素纳入更新的Lung-molGPA预后指数。
- 原DS-GPA基于1985至2005年诊断的1833例NSCLC脑转移患者的4项因素:年龄、Karnofsky体能状态、颅外转移和脑转移数目。
主要发现
- 原DS-GPA患者自脑转移初始治疗起中位生存7个月。
- 本队列全队列中位生存12个月;腺癌且Lung-molGPA评分3.5至4.0者中位生存接近4年。
- 显著预后因素包括原DS-GPA的4项因素,加上腺癌患者的EGFR和ALK改变(非腺癌未常规检测突变状态)。
关键数值与推荐
- Lung-molGPA评分3.5至4.0(腺癌)对应中位生存接近4年。
- 全队列中位生存12个月,原DS-GPA队列中位生存7个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. OBJECTIVE: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases. The DS-GPA is based on data from patients diagnosed between 1985 and 2005, and we set out to update it by incorporating more recently reported gene and molecular alteration data for patients with NSCLC and brain metastases. This new index is called the Lung-molGPA. DESIGN, SETTING, AND PARTICIPANTS: This is a multi-institutional retrospective database analysis of 2186 patients diagnosed between 2006 and 2014 with NSCLC and newly diagnosed brain metastases. The multivariable analyses took place between December 2015 and May 2016, and all prognostic factors were weighted for significance by hazard ratios. Significant factors were included in the updated Lung-molGPA prognostic index. MAIN OUTCOMES AND MEASURES: The main outcome was survival. Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios. Log rank tests were used to compare adjacent classes and to compare overall survival for adenocarcinoma vs nonadenocarcinoma groups. RESULTS: The original DS-GPA was based on 4 factors found in 1833 patients with NSCLC and brain metastases diagnosed between 1985 and 2005: patient age, Karnofsky Performance Status, extracranial metastases, and number of brain metastases. The patients studied for the creation of the DS-GPA had a median survival of 7 months from the time of initial treatment of brain metastases. To design the updated Lung-molGPA, we analyzed data from 2186 patients from 2006 through 2014 with NSCLC and newly diagnosed brain metastases (1521 adenocarcinoma and 665 nonadenocarcinoma). Significant prognostic factors included the original 4 factors used in the DS-GPA index plus 2 new factors: EGFR and ALK alterations in patients with adenocarcinoma (mutation status was not routinely tested for nonadenocarcinoma). The overall median survival for the cohort in the present study was 12 months, and those with NSCLC-adenocarcinoma and Lung-molGPA scores of 3.5 to 4.0 had a median survival of nearly 4 years. CONCLUSIONS AND RELEVANCE: In recent years, patient survival and physicians' ability to predict survival in NSCLC with brain metastases has improved significantly. The updated Lung-molGPA incorporating gene alteration data into the DS-GPA is a user-friendly tool that may facilitate clinical decision making and appropriate stratification of future clinical trials.
引用
- Sperduto PW, Yang TJ, Beal K, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017. PMID: 27892978. doi:10.1001/jamaoncol.2016.3834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。